Savara Inc (NASDAQ:SVRA) Shares Sold by Swiss National Bank

Swiss National Bank lessened its position in shares of Savara Inc (NASDAQ:SVRA) by 6.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 178,000 shares of the company’s stock after selling 12,800 shares during the period. Swiss National Bank’s holdings in Savara were worth $546,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of Savara during the third quarter worth about $67,000. BNP Paribas Financial Markets increased its holdings in shares of Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after buying an additional 18,534 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after buying an additional 4,732 shares during the period. SG Americas Securities LLC boosted its stake in Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after purchasing an additional 6,330 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in Savara in the 3rd quarter worth about $174,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

NASDAQ SVRA opened at $2.91 on Monday. The company has a 50 day moving average price of $2.72 and a two-hundred day moving average price of $3.25. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.34. The stock has a market capitalization of $499.41 million, a PE ratio of -6.77 and a beta of 0.60. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. As a group, equities analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SVRA shares. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Savara in a research note on Friday. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. Finally, Wells Fargo & Company began coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.